Project Grant HT94252410794
Award Date 8/1/24
Completion Date 7/31/26
Dollars Obligated $420K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- This $499,300 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research by Myogene Bio LLC, a woman-owned small business in San Diego, California, to advance manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy (DMD). The key products and services to be delivered include: 1) Optimizing the upstream...
- The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded a $302,500 Project Grant to Myogene Bio LLC, a woman-owned small business in San Diego, California. The grant, provided under NICHD's Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to assess the use of a restored dystrophin protein as a biomarker for evaluating the efficacy of a gene editing therapy for Duchenne muscular dystrophy (DMD). The...
- The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
- This federal Project Grant award, with $405,341 in funding from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), supports research by the Children's Research Institute to explore the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). The 3-year project, running from August 1, 2025 to July 31, 2028, aims to develop innovative medical solutions to address this critical health challenge...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...
- This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
- This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
- The U.S. Defense Health Agency awarded a $777,659 Project Grant to the Children's Research Institute in Washington, DC under the Military Medical Research and Development program (CFDA 12.420). The grant funding, which covers the period from August 1, 2025 to July 31, 2028, will support the institute's research on the use of pro-resolution and restorative pharmacology approaches for the treatment of Duchenne muscular dystrophy (DMD). As a non-profit pediatric research organization, the...
- This federal Project Grant award of $513,653.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by the University of Arkansas to develop self-delivering gene editors for the correction of Duchenne muscular dystrophy. The award period runs from August 15, 2024 to August 14, 2026, and aligns with the program's goal of transforming healthcare for military service members and the broader public through innovative...